NDRG2 Is a Novel p53-Associated Regulator of Apoptosis in C6-Originated Astrocytes Exposed to Oxygen-Glucose Deprivation

Li, Yan; Xu, Ning; Cai, Lei; Gao, Zijun; Shen, Lan; Zhang, Qiaomei; Hou, Wugang; Zhong, Haixing; Wang, Qiang; Xiong, Lize
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
N-myc downstream-regulated gene 2 (NDRG2) has been documented to be a pro-differentiative and anti-proliferative gene in cancer research. Our previous study found a significant NDRG2 up-regulation in reactive astrocytes of penumbra after transient focal cerebral ischemia, which was parallel to the enhancement of TUNEL-positive signals. However, it is still uncertain whether NDRG2 participates in cellular apoptosis induced by ischemia-reperfusion injury in brain. In this study, we investigated the role of NDRG2 in cellular apoptosis induced by oxygen-glucose deprivation (OGD) in IL-6-differentiated C6 glioma cells. The results showed that NDRG2 was up-regulated and translocated from the cytoplasm to the nucleus after OGD exposure. NDRG2 over-expression exhibited an anti-proliferative effect and increased the Bax/Bcl-2 ratio after OGD exposure, while NDRG2 silencing promoted the cellular proliferation and attenuated the up-regulation of Bax/Bcl-2 ratio. The pro-apoptotic effect of p53 was verified by the results in which p53 silencing greatly reduced the percentage of OGD-induced apoptotic cells. p53 silencing also reduced the OGD-induced NDRG2 up-regulation. However, over-expression of p53 did not further improve the NDRG2 up-regulation. In conclusion, NDRG2 is a p53-associated regulator of apoptosis in C6-originated astrocytes after OGD exposure. These findings bring insight to the roles of NDRG2 in ischemic-hypoxic injury and provide potential targets for future clinical therapies on stroke.


Related Articles

  • Inactivation of HAUSP in vivo modulates p53 function. Kon, N.; Kobayashi, Y.; Li, M.; Brooks, C. L.; Ludwig, T.; Gu, W. // Oncogene;3/4/2010, Vol. 29 Issue 9, p1270 

    Hausp is a deubiquitinase that has been shown to regulate the p53–Mdm2 pathway. Cotransfection of p53 and Hausp stabilizes p53 through the removal of ubiquitin moieties from polyubiquitinated p53. Interestingly, knockout or RNA interference-mediated knockdown of Hausp in human cells also...

  • Progesterone Attenuates Aquaporin-4 Expression in an Astrocyte Model of Ischemia/Reperfusion. He, Lu; Zhang, Xiaoyang; Wei, Xianfeng; Li, Yunsheng // Neurochemical Research;Nov2014, Vol. 39 Issue 11, p2251 

    Previous studies have suggested that progesterone may be involved in neuroprotection by preventing brain edema. In this study, we assessed the effects of progesterone on aquaporin-4 (AQP4) expression in an ischemia/reperfusion model of cultured rat astrocytes, and further explored the possible...

  • Quercetin Protects Against Oxidative Stress Associated Damages in a Rat Model of Transient Focal Cerebral Ischemia and Reperfusion. Ahmad, Ajmal; Khan, Mohd.; Hoda, Md.; Raza, Syed; Khan, M.; Javed, Hayate; Ishrat, Tauheed; Ashafaq, Mohammad; Ahmad, Md.; Safhi, Mohammed; Islam, Fakhrul // Neurochemical Research;Aug2011, Vol. 36 Issue 8, p1360 

    Experimental studies have demonstrated that oxidative stress and apoptosis play an important role in cerebral ischemic pathogenesis and may represent a target for treatment. The purpose of this study was to determine whether the quercetin dihydrate (Q) protects against cerebral ischemia neuronal...

  • Small-Molecule Inhibitors of p53-MDM2 Interaction: the 2006-2010 Update. Millard, Melissa; Pathania, Divya; Grande, Fedora; Shili Xu; Neamati, Nouri // Current Pharmaceutical Design;2/21/2011, Vol. 17 Issue 6, p536 

    No abstract available.

  • Small Molecules Targeting p53 to Improve Antitumor Therapy. Beretta, G. L.; Gatti, L.; Benedetti, V.; Perego, P.; Zunino, F. // Mini Reviews in Medicinal Chemistry;Aug2008, Vol. 8 Issue 9, p856 

    Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of...

  • Apoptotic response of malignant rhabdoid tumor cells. Nocentini, Silvano // Cancer Cell International;2003, Vol. 3, p11 

    Background: Malignant rhabdoid tumors (MRTs) are extremely aggressive and resist current radio- and chemotherapic treatments. To gain insight into the dysfunctions of MRT cells, the apoptotic response of a model cell line, MON, was analyzed after exposure to several genotoxic and non-genotoxic...

  • Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale. Pommier, Yves; Sordet, Oliver; Rao, V. Ashutosh; Zhang, Hongliang; Kohn, Kurt W. // Current Pharmaceutical Design;Aug2005, Vol. 11 Issue 22, p2855 

    Most anticancer drugs presently used clinically target genomic DNA. The selectivity of these anticancer drugs for tumor tissues is probably due to tumor-specific defects suppressing cell cycle checkpoints and DNA repair, and enhancing apoptotic response in the tumor. We will review the molecular...

  • Regulation of p53 Stability and Apoptosis by a ROR Agonist. Wang, Yongjun; Solt, Laura A.; Kojetin, Douglas J.; Burris, Thomas P. // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Activation of p53 function leading to cell-cycle arrest and/or apoptosis is a promising strategy for development of anticancer therapeutic agents. Here, we describe a novel mechanism for stabilization of p53 protein expression via activation of the orphan nuclear receptor, RORα. We...

  • Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423. Kashiyama, Tomoko; Oda, Katsutoshi; Ikeda, Yuji; Shiose, Yoshinobu; Hirota, Yasuhide; Inaba, Kanako; Makii, Chinami; Kurikawa, Reiko; Miyasaka, Aki; Koso, Takahiro; Fukuda, Tomohiko; Tanikawa, Michihiro; Shoji, Keiko; Sone, Kenbun; Arimoto, Takahide; Wada-Hiraike, Osamu; Kawana, Kei; Nakagawa, Shunsuke; Matsuda, Koichi; McCormick, Frank // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    DS-7423, a novel, small-molecule dual inhibitor of phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), is currently in phase I clinical trials for solid tumors. Although DS-7423 potently inhibits PI3Kα (IC50 = 15.6 nM) and mTOR (IC50 = 34.9...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics